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Abstract
Significance: Lysosomes are organelles in which cellular degradation occurs in a controlled manner, separated
from other cellular components. As several pathways terminate in the lysosome, lysosomal dysfunction has a
profound impact on cell homeostasis, resulting in manifold pathological situations, including infectious diseases,
neurodegeneration, and aging. Recent Advances: Lysosomal biology demonstrates that in addition to regulating
the final steps of catabolic processes, lysosomes are essential up-stream modulators of autophagy and other
essential lysosomal pathways. Future Directions and Critical Issues: Lysosomal membrane permeabilization
offers therapeutic potential in the treatment of cancer, though the molecular regulators of this process remain
obscure. This review focuses on recent discoveries in lysosomal function and dysfunction, primarily in in vivo
situations. Antioxid. Redox Signal. 17, 766–774.
Introduction: The Lysosome
Lysosomes are cytoplasmic membrane-enclosed organ-elles containing hydrolytic enzymes that degrade macro-
molecules and cell components (38). These organelles were
discovered by Christian de Duve over 60 years ago, for which,
among other discoveries, he received theNobel Price award in
1974 (5). For some time the lysosome was considered the final
destination of degradative pathways. However, interest in
this organelle has been revived due to its implication in a
plethora of important processes in cells and tissues. This re-
view will summarize some of the recent findings demon-
strating the importance of lysosomes in many physiological
conditions and the role of lysosomal dysfunction in patho-
logical conditions.
With the exception of erythrocytes, lysosomes are found in
all eukaryotic cell types. However, not all lysosomes are alike
and some have acquired specific functions in given cell types,
such as melanosomes and lytic granules, which are modified
lysosomes also known as lysosome-related organelles (38).
Lysosomes contain many different hydrolytic enzymes, in-
cluding proteases, lipases, nucleases, glycosidases, phospho-
lipases, phosphatases, and sulfatases, which usually exert
maximal enzymatic activity at low pH. This acidic milieu of
lysosomes (pH £ 5) is maintained by a vacuolar ATPase that
pumps protons from the cytoplasm into the lysosomal lumen
(38). Other important lysosomal components include lyso-
somal membrane proteins that play diverse and crucial roles
in lysosome homeostasis. These proteins, such as Lamp-1 and
Lamp-2, are heavily glysosylated and hence resist digestion,
protecting the lysosomal membrane from acidic hydrolases
(38) and agents that can damage the lysosome (8). Lysosomal
membrane proteins also regulate lysosomal movement, cel-
lular distribution, and exocytosis (38).
How lysosomal biogenesis occurs is not completely un-
derstood (38). A recent report shows that site-1 protease
(S1P), a metalloprotease embedded in the Golgi membrane
that regulates cholesterol metabolism, is required for lyso-
some biogenesis. Cells lacking S1P display a characteristic
lysosomal defect; rather than being targeted to the organelle,
certain lysosomal enzymes are secreted out of the cells (22).
New evidence demonstrates that many lysosomal genes are
regulated in a coordinated fashion by transcription factor EB
(TFEB) (42). This transcription factor, which belongs to the
microphatalmia-transcription factor E family, binds to a
palindromic 10 bp sequence (known as the CLEAR element),
which is found in many lysosomal genes, including cathe-
psines and lysosomal membrane proteins (42). Over-
expression of TFEB in HeLa cells induces a clear expansion
of the lysosomal compartment and increases the number of
lysosomes per cell. This transcription factor translocates to
the nucleus after lysosomal stress and exhibits a predomi-
nantly nuclear distribution in MEFs from patients with
several forms of lysosomal storage diseases (LSD) (42). In
addition to regulating lysosomal genes, TFEB also regulates
the expression of several autophagy-related genes in nutrient-
deprived conditions, in which autophagy is activated as a
cytoprotective response (43). Interestingly, TFEB also links
mTOR to V-ATPase expression and endocytosis (33). Thus,
by regulating lysosomal biogenesis, TFEB emerges as an
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essential coordinator of the autophagy-lysosomal response
after stress.
Pathways Converging in Lysosomes
Several degradation pathways converge at the level of the
lysosome, including endocytosis, phagocytosis, and autop-
hagy (Fig. 1). The two first pathways degrade components
from the extracellular milieu (heterophagy), while macro-,
micro-, and chaperone-mediated autophagy (CMA) mainly
degrade intracellular components (49). During macro-
autophagy cytoplasmic components, damaged proteins and
entire organelles are degraded and recycled to generate
building blocks for anabolic processes (49). CMA is a process
by which cystosolic proteins harboring a motif with specific
amino acid sequences are incorporated into lysosomes
through the combined action a chaperone (usually Hcs70) and
the lysosomal receptor Lamp-2A. Much less is known about
microautophagy, whereby macromolecules are directly
translocated into the lysosomal lumen for degradation (49).
As the main catabolic organelle in the cell, lysosomes de-
grade a plethora of compounds, including surface receptors,
macromolecules, organelles, and pathogens (Fig. 2), as well as
some short-lived proteins previously thought to be degraded
by the proteasome system, such as p27 and the small GTPase
RhoB (9, 34). Lipid modifications in the eight amino acid se-
quence of the C-terminus of this short-lived GTPase mediate
the rapid degradation of both RhoB and chimeric proteins
bearing this sequence, via the lysosomal pathway (34). In
addition, lysosomes also degrade intracellular organelles that
reach the lysosomal lumen trough macroautophagy, such
as mitochondria—in a process now called mitophagy—
ribosomes, peroxisomes, and endoplasmic reticulum. Al-
teration on some of these pathways may have important
implication in diseases such as cancer and neurodegeneration.
Lysosomal Function: New Insights
Several recent findings have demonstrated the central role of
the lysosome in controlling cellular responses to nutrients.
Mammalian target of rapamycin complex 1 (mTORC1) is a
kinase that regulates the cellular response to amino acids,
growth factors, and energy levels within the cell. mTORC1
translocates to the lysosomal membrane in the presence of
amino acids, where it is activated by its modulator Rheb (41).
This translocation is regulated by a multiprotein complex
named Ragulator, which serves as an aminoacid-regulated
docking site for mTORC1 on lysosomal membranes. At this
location mTORC1 phosphorylates downstream effectors that
modulate cellmetabolism andblock autophagy.A recent study
by Narita et al. further linked lysosomes and mTORC1 (29),
demonstrating that lysosomes spatially link mTOR and au-
tophagy in a compartment known as TOR-autophagy spatial
coupling compartment during Ras-induced senescence. This
proximity of autolysosomes and the Golgi apparatus to
mTORC1 links autophagy-dependent protein degradation to
mTOR-dependent secretory protein synthesis. This paradoxi-
cal phenotype is observed in senescent cells that display a high
FIG. 1. Pathways converging in lysosomes.
FIG. 2. Lysosomal functions.
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level of autophagy induction and extensive secretory protein
synthesis (29).
Other findings have demonstrated the importance of
compartmentalization and lysosomal positioning within the
cell in controlling cellular nutrient responses (17). In con-
ditions of nutrient starvation, lysosomes cluster in the
perinuclear area of the cell, where autophagosomes are pre-
dominantly localized. Autophagosome–lysosome fusion
permits degradation and recycling to provide new building
blocks andmaintain cell functions. In nutrient-rich conditions,
however, lysosomes move along microtubules to a more pe-
ripheral localization (17). Lysosomal positioning regulates
mTOR signaling; recovery after starvation restores lysosomal
localization of mTORC1 and its autophagy-inhibiting activity
(17). The reverse, however, does not hold true; mTORC1 ac-
tivity does not influence lysosomal localization or redistri-
bution, pointing to the lysosome as the upstream regulator of
this process (17). Yu et al. further linked mTORC1 to the ly-
sosome, demonstrating that despite an initial period of
mTORC1 inhibition shortly after nutrient starvation (2 h),
longer incubation in these conditions (over 6 h) induces
mTORC1 activation, as evidenced by an increase in the
phosphorylation of its downstream target S6K (50). More
importantly, this effect is dependent on the autophagy regu-
lators Atg5 andAtg7 and on lysosomal proteolysis, indicating
that autophagy and lysosomal degradation regulatemTORC1
activation to terminate the autophagic process (50). Lyso-
somes thus control both the final step during nutrient star-
vation (lysosomal degradation) and the initiation of the
process (autophagy induction).
Yu and colleagues also provided new clues regarding the
recycling of lysosomal proteins and the membrane during
starvation. They define the concept of autophagic lysosome
reformation (ALR) as an evolutionarily conserved regeneration
mechanism that controls nutrient sensing and lysosome ho-
meostasis after nutrient deprivation (37, 50). During mTORC1
activation after prolonged starvation, tubular structures pro-
trude from the autolysosomal membranes, growing to form
vesicles that finally pinch off to give rise to protolysosomes.
These new isolated organelles are positive for lysosomal
membrane markers such as Lamp-1, though they do not stain
for the acidic probe LysoTracker Red or endocytosed dextrans,
indicating that these structures permit recycling of lysosomal
membrane but not the autolysosomal contents (50). Incubation
with rapamycin during starvation prevents ALR, indicating
that this process is mTORC1 dependent. mTORC1-regulated
ALR thus provides feedback inhibition to terminate autophagy
after prolonged starvation, aswell asmediating recycling of the
lysosomal membrane and membrane proteins through the
formation of protolysosomes from the autophagolysosomal
membrane (50). Recently, the lysosomal permease Spinsterwas
identified as the regulator of mTORC1 reactivation and ALR
following prolonged starvation (37). Taken together, this new
evidence points to lysosomes, not upstream regulators, as es-
sential and active players in the control of cellular responses to
nutritional stress.
Lysosomal Pathways in Development
and Differentiation
Few studies have addressed the role of lysosomal function
during development. Cathepsin D (CD) and the acid-DNAse
II appear to be overexpressed in areas of prominent cell
death during limb and heart development (27). CD is ex-
pressed during insect metamorphosis in a tissue-specific and
developmental-stage-specific manner, and transcriptionally
regulated by the hormone ecdysone. RNAi depletion of CD
arrests larval–pupal metamorphosis and abolishes DNA
fragmentation (12). Cathepsin activity during insect devel-
opment may be related to the involvement of autophagy and
lysosome degradation in Drosophilametamorphosis, in which
both autophagy and caspases play prominent roles (24). The
roles of lysosomes and autophagy during development ap-
pear to be related to programmed cell death. Indeed, autop-
hagy is indispensable for apoptotic cell removal during retinal
development (25), though this effect appears to be specific to
cell death in neuroblasts and recently born neurons, without
affecting the elimination of apoptotic bodies from mature
neurons (26). A similar phenotype of defective clearance has
been described in a Drosophila model of the LSD Mucolipi-
dosis type IV (44).
During development cell fate decisions influenced by
morphogens are required for embryo patterning. Recent evi-
dence demonstrates that the rate at which internalized mor-
phogen receptors are trafficked to lysosomes is crucial for
sensing morphogen gradients during development (32).
Other studies have demonstrated the importance of the en-
dolysosomal pathway for axon pathfinding and synapse
formation. Loss of the neuron-specific v-ATPase subunit a1 in
Drosophila leads to the progressive accumulation of the en-
dosomal guidance receptor, altering its turnover and signal-
ing after neuronal differentiation (47). Recent findings have
also demonstrated a key role for lysosomes in mammary
gland remodeling after lactation (see below). Lysosomes thus
play different roles during development and differentiation,
detecting morphogen gradients, remodeling intracellular
components during cell differentiation, and participating in
cell demise, either by directly inducing cathepsin-dependent
cell death or by degrading apoptotic cells.
The Roles of Lysosomes in Programmed Cell Death:
Lysosomal Membrane Permeabilization
Given their high levels of hydrolytic enzymes, lysosomes
are potentially harmful to the cell (3). Damage to the lyso-
somal membrane results in the release of its contents into the
cytoplasm, inducing indiscriminate degradation of cellular
components. Moreover, massive lysosomal breakdown may
induce cytosolic acidification, which in turn can induce cell
death by necrosis (Fig. 3). This concept was first described by
Christian de Duve, who termed lysosomes ‘‘suicide bags’’ (5).
However, as discussed in the proceeding section, partial and
selective lysosomal membrane permeabilization (LMP) in-
duces controlled cell death.
LMP provokes the translocation of lysosomal contents to
the cytoplasm. The proteases implicated in cell death are ca-
thepsins that remain active at neutral pH, such as cathepsin B,
CD, and cathepsin L (3). These proteases trigger a cascade of
events culminating in the activation of apoptotic effectors
(Fig. 3), including mitochondria, caspases, and other as-
yet-unknown effectors (3). Specific methods to identify LMP
in cells and tissues have been previously reviewed (3, 13).
A continually growing list of compounds can induce LMP
(3, 10, 14). An updated list of those classified according to
768 BOYA
family is shown in Figure 4. However, the role of these com-
pounds in inducing LMPwill not be discussed here. Cells also
contain endogenous inhibitors that can protect against lyso-
somal damage; the Hsp70 family of chaperones has been
shown to protect lysosomal membranes from damaging
agents (16). Moreover, by binding to the lysosomal lipid an-
ionic phospholipid bis(monoacylglycero)phosphate, recom-
binant Hsp70 can reverse the phenotype seen in patients with
Niemann-Pick disease A, an LSD associated with decreased
lysosomal stability (16). Calpain-mediated cleavage of Hsp70
was recently described in CA1 neurons of the monkey hip-
pocampus after ischemia-reperfusion insult (39). Further
supporting the protective role of Hsp70 in lysosomal function,
2-phenylethynesulfonamide, an inhibitor of the Hsp70 activ-
ity, suppresses tumor development in vivo (20).
Although numerous studies have demonstrated lysosomal-
mediated cell death in culture, no clear evidence of LMP has
been reported during physiological cell death. Recently,
LMP-induced cell death has been implicated in the regres-
sion of the mammary gland after lactation (18). This process
occurs upon weaning and involves the controlled elimination
of mammary gland cells by programmed cell death. In the
first phase of postlactation regression, lysosomes become
leaky and cathepsines B and L are translocated to the cyto-
plasm, inducing caspase-independent cell death. The molec-
ular regulation of this LMP remains elusive, though a
FIG. 3. Cell death pathways after lyso-
somal membrane permeabilization.
FIG. 4. Agents that induce
lysosomal membrane per-
meabilization.
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decrease in the expression of the lysosomal membrane pro-
tein Lamp-2, which precedes LMP in other systems (7), is
observed after lactation. In addition to the increased sensi-
tivity to LMP during involution of the mammary gland, the
expression profile of protein precursors of cathepsines B and
L increases sharply after weaning, accompanied by an in-
crease in the presence of the active forms in the supernatant
of purified lysosomes, indicating lysosomal leakage (18).
Kreuzaler and colleagues further demonstrated that Stat3
controls the expression of these proteins and that specific
deletion of this transcription factor in the mammary gland
significantly delays postlactation regression. More impor-
tantly, in vivo administration of the cathepsine B inhibitor
CA-074-Me significantly delays cell death and the regression
of the mammary gland, indicating that LMP is a crucial
event in this process (18). These recent findings link Stat3
with LMP in a physiological cell death paradigm. Whether
these findings can aid the search for new therapies for
mammary tumors remains to be demonstrated. While cas-
pases are activated during mammary gland involution,
postlactation regression proceeds as normal in caspase-defi-
cient animals, suggesting that caspase activation during this
process may be a consequence, rather than a cause, of cell
death (18). Besides classical morphology of apoptotic cells,
studies using bovine mammary gland remodeling have
identified cells loaded with autophagosomes that would be
classified as undergoing type-II or autophagic cell death
according to the old-morphological definitions of cell death.
Autophagy induction as determined by electron microscopy,
as well as LC3 and Beclin1 upregulation, is observed during
mammary gland remodeling. However, careful examination
indicates that the autophagy process may be activated as a
consequence of cell starvation or as a cytoprotective mech-
anism to prevent cell death (28). Whether autophagy also
provides an efficient mechanism for cell remodeling during
mammary gland involution remains to be elucidated.
Relatively few in vivo studies have addressed the relation-
ship between lysosomal membrane destabilization and
pathogenic cell death [for early reports please refer to Ref. (3)].
A recent report demonstrates that LMP followed by CD-
dependent macrophage killing is essential for clearance of
pneumococcal infection in vivo (2). While LMP clearly induces
cell death, the molecular events that lead to lysosomal mem-
brane leakage remain obscure; LMP may occur through
nonselective rupture of the membrane or alternatively,
though the formation of specific pores that allow the selective
translocation of molecules up to a certain size through the
partially permeable lysosomal membrane.
Lysosomes in Cancer Therapy
The capacity of lysosomes to kill cells through LMP has
been exploited in the development of cancer treatments. A
wide variety of agents can kill cancer cells in vitro [for reviews
see Refs. (3, 10)] (Fig. 4). To develop efficient and nontoxic
cancer therapies, a distinction must be made between healthy
Table 1. Recently Described Models and Diseases Associated with Lysosomal Dysfunction
Disease Model Cause
Lysosomal
dysfunction Consequences Reference
AD PS1 mutation Presenilin 1
mutations
Increased pH by de-
creased lysosomal
ATPase expression
Autophagy block,
neurodegeneration
(30)
AD Fly, mouse and
sheep models of
CD deficiency
Tau cleavage,
caspase activation
Defect in CD Neurodegeneration (15)
Synuclenopathies/
Gaucher disease
Glucocerebrosidase
deficiency/Gau-
cher disease mice
and patients
Glucocerebrosidase
deficiency
Inhibition of lyso-
somal activity
a-synuclein accumu-
lation, neurode-
generation
(23)
PD MMP + treated
mice/PD patients
Oxidative stress?
Mitochondrial
damage?
LMP Autophagy block,
neurodegeneration
(7)
Lafora disease EPM2A (laforin -/–) Decreased laforin
expression
Decreased autop-
hagy, ubiquitin
accumulation
Glycogen storage
disease, neurode-
generation
(1)
Mucolipidosis
type IV
Drosophila Secondary death in
adjoining cells
Defective clearance
of apoptotic cells
Motor deficits (44)
Mucolipidosis II? S1P deficient cells Defects in the target-
ing of lysosomal
enzymes
Lysosomal dysfunc-
tion
Lysosomal enzyme
targeting defects
(22)
Pneumococcal
infection
CD -/ - Cathepsin deficiency Infected macrophage
LMP
Decreased
apoptosis of
macrophages and
bacterial killing
(2)
Ischemia-reperfusion
insult
Monkey hippocam-
pal CA1 neurons
Cleavage of Hsp70
by calpain
LMP Neurodegeneration (39)
AD, Alzheimer’s disease; CD, cathepsin D; LMP, lysosomal membrane permeabilization; MMP+ , N-methyl-4-phenylpyridinium; S1P, site-1
protease; PD, Parkinson’s disease.
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and tumor cells, since all cells contain lysosomes. However,
lysosomes from cancer cells exhibit several properties that
differ from those of un-transformed cells, which may be
exploited in therapeutic strategies. During cellular transfor-
mation, cancer cells undergo profound lysosomal changes,
affecting size, intracellular localization, cathepsin expression,
and enzymatic activity. Moreover, several findings suggest
that lysosomes from cancer cells may be more susceptible to
LMP. For example, the increased size of lysosomes in cancer
cells renders them more susceptible to destabilizing agents
(11). Furthermore, mutations that disrupt components of the
lysosomal degradation pathway were found to contribute to
tumor development and progression in a genetic screen per-
formed in Drosophila (4). A recent report demonstrated that
autophagy induction and LMP-dependent cell killing medi-
ate the antitumoral effects of the cannabinoid delta(9)-
tetrahydrocannabinol (THC) against glioma (40). Moreover, a
strategy combining Akt inhibition with lysosomotropic
agents that disturb lysosomal stability (chloroquine) exerted
antitumoral effects in vivo (6). Exploitation of LMP-mediated
cell killing for cancer therapy thus represents a new and po-
tentially beneficial therapeutic avenue for the treatment of
human tumors.
Lysosomal Dysfunction
LSDs are pathologies in which a lysosomal defect provokes
aberrant intra-lysosomal accumulations of undigested mate-
rials. To date, over 50 monogenic human genetic diseases
associated with lysosomal dysfunctions have been identified.
Although these diseases are triggered by a monogenic mu-
tation, the underlying molecular and cellular events are
highly complex and remain unclear (46). The most common
mutations in these diseases are found in soluble lysosomal
enzymes, nonenzymatic lysosomal proteins (soluble or
membrane-bound), and nonlysosomal proteins that regulate
lysosomal functions such as lysosomal protein trafficking (46).
These diseases are inherited in an autosomal recessive man-
ner, and the residual activity of the mutated protein deter-
mines the disease penetrance. Null mutations trigger
symptoms in utero or during early childhood, while milder
mutations lead to juvenile or adult onset disease (46). The
downstream consequences of LSD usually include altered li-
pid trafficking, calcium homeostasis, and inflammation that
contribute to pathogenesis (46). Moreover, since lysosomes
are the final step in the autophagy process, lysosomal alter-
ations have profound defects on autophagy and autophago-
some accumulation, as has been reported in many LSDs
(Table 1).
Neurodegeneration associated with lysosomal and autop-
hagy dysfunction has been well documented (31, 36). Alz-
heimer’s disease (AD) is the most common cause of dementia,
the prevalence of which increases with age. Several observa-
tions point to defective lysosomal function in this disease (30).
Furthermore, an unexpected link has been reported between
AD and defective lysosomal proteolysis associated with re-
duced acidification of lysosomes (19). The presenilin 1 protein,
which is often mutated in AD, is essential for translocation of
the v-ATPase V0a1 subunit to lysosomes (19). Reduced levels
of this lysosomal ATPase decrease lysosomal acidification,
hampering protease activation and blocking lysosomal func-
tion (19). Accordingly, presenilin 1 deletion reduces the
degradation of autophagic/lysosomal substrates. Similar
autolysosome maturation defects have been described in
neurons in the brains of mouse models of PS1 hypofunction
and in cells from AD patients with presenilin 1 mutations. A
further link between AD and lysosomal activity is suggested
by recent evidence demonstrating abnormal C-terminal
truncation of tau and accompanying caspase activation inCD-
deficient animals (15).Moreover, inmicewith genetic deletion
of cystatin B, an endogenous inhibitor of lysosomal cysteine
proteases, abnormal accumulations of amyloid-b peptide,
ubiquitinated proteins, and other autophagic substrates within
autolysosomes/lysosomes are attenuated, and neurodegen-
eration-associated learning and memory defects prevented
(48). Together, these findings support the role of proper lyso-
somal function in preventing neurodegeneration.
In a mouse model of Parkinson’s disease (PD), autopha-
gosome accumulation and dopaminergic cell death is pre-
ceded by a marked decrease in levels of the lysosomal
proteins Lamp-1 and Lamp-2, and a reduction in lysosomes
within dopaminergic neurons (7). Lysosomal depletion occurs
secondary to the abnormal permeabilization of lysosomal
membranes induced by increased mitochondrial-derived re-
active oxygen species. LMP resulted in defective clearance
and subsequent accumulation of undegraded autophago-
somes and contributed directly to neurodegeneration by
subsequent ectopic release of lysosomal proteases into the
cytoplasm (7). Lysosomal breakdown and autophagosome
accumulation is also observed in PD brain samples, in which
Lewy bodies are strongly immunoreactive for autophagoso-
mal markers. Importantly, induction of lysosomal biogenesis
by genetic or pharmacological activation of lysosomal TFEB
restores lysosomal levels, increases autophagosome clear-
ance, and attenuates cell death. The autophagy-enhancer
compound rapamycin attenuates PD-related dopaminergic
neurodegeneration, both in vitro and in vivo, by restoring ly-
sosomal levels. Similar changes occur in PD brain samples, in
which Lewy bodies appear to derive from undegraded au-
tophagosomes (7). These results indicate that autophagosome
accumulation in PD results from defective lysosomal-
mediated autophagosome clearance secondary to lysosomal
depletion. Restoration of lysosomal levels and function may
thus represent a novel neuroprotective strategy for the treat-
ment of PD (45).
Pathologic accumulation of alpha-synuclein is a feature of
PD and other neurodegenerative diseases called synucleino-
pathies. In vivo, this protein is degraded by lysosomal
pathways and in particular by CMA (21). A link between a-
synucleinopathies andLSDwas recently proposed. a-synuclein
accumulation is associatedwith a reduction in the expression of
glucocerebrosidase, the lysosomal enzymemutated inGaucher
disease (23). Biochemical analysis demonstrated that gluco-
cerebrosidase deficiency increases the levels of soluble a-
synuclein oligomers, resulting in aggregation-dependent
neurotoxicity. This was a specific effect, as general lysosomal
inhibition with leupeptin increased the levels of insoluble
forms only. Moreover, a-synuclein inhibited the lysosomal ac-
tivity of glucocerebrosidase, generating a positive feedback
loop and leading to neurodegeneration. Taken together, these
findings demonstrate a key role of glucocerebrosidase deple-
tion in the pathogenesis of sporadic synucleopathies (23).
Lafora disease is a fatal autosomal recessive genetic disor-
der also known as Lafora progressivemyoclonic epilepsy. The
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disease is characterized by the presence of inclusion bodies,
known as Lafora bodies, within the neurons and cells of the
heart, liver, and skin. Mutations in this pathogenic condition
occur in the EPM2A and EPM2B genes, which encode the
laforin and malin proteins, respectively. Patients with Lafora
disease suffer a neurodegenerative disorder associated with
progressive intellectual decline and ataxia in addition to epi-
lepsy. Lafora bodies are composed of abnormal glycogen ac-
cumulations called polyglucosans, which are insoluble and
thus precipitate inside cells. Although the molecular patho-
genesis of the disease remains poorly understood, it has been
proposed to be a defective clearance disorder. In addition to
enzymatic degradation in the cytosol, glycogen is degraded in
lysosomes by acid alpha-glucosidase (also known as acid
maltase), via the autophagy–lysosomal system. The im-
portance of this autophagy–lysosomal pathway of glyco-
gen degradation is illustrated in glycogen storage disease
type II, or Pompe disease, in which this single lysosomal
enzyme is lacking (35). Recent studies have demonstrated
that laforin regulates autophagy in an mTOR-dependent
manner (1). Moreover, cells from laforin-deficient patients
and mouse embryonic fibroblasts from laforin-deficient
mice exhibit reduced levels of LC3-II and accumulations of
poli-ubiquitinated proteins and the autophagy substrate
p62 (1). Together, these findings demonstrate the regula-
tory role of laforin in autophagy and suggest that its ab-
sence and the associated defects in autophagy could
predispose Lafora disease patients to neurodegeneration.
The effect of malin mutations on autophagy and lysosomal
pathways in Lafora disease remains to be elucidated. Ly-
sosomal dysfunction thus appears as a common hallmark in
many pathological conditions, including LSD, neurode-
generation, and aging.
Concluding Remarks and Future Directions
Lysosomes are no longer considered the garbage bags in
which cellular waste is disposed, but rather have emerged as
crucial regulators of cell homeostasis. Recent findings have
demonstrated the coupling of lysosomal biogenesis and the
stress response via the transcription factor TFEB, and new and
unexpected links between lysosomes and the essential kinase
mTORC1 have been described. Lysosomes regulate mTOR
subcellular localization and activity, thus forming a feedback
loop that links upstream signals to tightly regulated catabolic
reactions. In turn, mTOR controls the recycling of the lyso-
somal membrane and proteins through the evolutionarily
conserved ALR pathway, generating a proto-lysosome that
gives rise to a fully functional mature lysosome. Compart-
mentalization also emerges as a new regulatory control point
in lysosome biology. The subcellular localization of lysosomes
controls their activity, and physical proximity appears to be
important to simultaneously couple protein synthesis
and degradation, two processes previously thought to be
incompatible.
New evidence has provided proof that LMP occurs in vivo
during physiological cell death in mammary gland involu-
tion. Whether this can be exploited for new therapies against
mammary and other tumors remains to be demonstrated.
Lysosomal dysfunction is a common hallmark associated
with many neurodegenerative conditions. Thus, therapies
aimed a restoring lysosomal function may have applications
for the treatment of diseases such as AD and PD. Further
understanding of lysosomal control of other cellular functions
and the identification of molecular regulators of LMP and
ARLwill be essential for the development of new therapies for
the treatment of infectious diseases, cancer, neurodegenera-
tion, and aging.
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